You are here

Memorial Sloan-Kettering Cancer Center

1275 York Avenue
New York, NY 10065
United States

Mentor Name: Oriana Miltiadous

Memorial Sloan-Kettering Cancer Center

Mentor Name: Julia Glade-Bender

Memorial Sloan-Kettering Cancer Center

Mentor Name: Nai-Kong Cheung

Memorial Sloan-Kettering Cancer Center

Desmoplastic small round cell tumor is a rare cancer that affects children and young adults. Most patients have very advanced disease already when they are diagnosed, and the long-term survival rate is low. Current treatments can't cure DSRCT and are very toxic. Patients who do survive are often left with debilitating side effects that last the rest of their lives. We have developed a new type of radiation therapy that targets the tumor cells specifically without harming normal tissue. In mice, this type of therapy can cure tumors without causing toxicity.

The gut microbiome plays a critical role in modulating the immune response, influencing outcomes of allogeneic transplantation, a life-saving treatment for relapsed/refractory leukemia and lymphoma. However, this treatment comes with significant complications that can limit is efficacy. Understanding and leveraging the immunomodulatory potential of the microbiome is crucial for optimizing cancer therapy outcomes. However, the mechanisms underlying the microbiome's influence on outcomes post-transplant, especially in pediatric patients, remain insufficiently understood.

Memorial Sloan-Kettering Cancer Center

Desmoplastic small round cell tumor (DSRCT) is one of the most aggressive pediatric sarcomas with a low survival rates despite the combination of aggressive chemotherapy, surgery, and radiation therapy. No targeted treatments are currently available and little is known about the biology of this tumor type. Although all patients harbor a very specific chromosomal rearrangements that generates a novel fusion gene, how this gene induces the development of cancer remains a mystery.

Pages